PMCC PMCC

Search tips
Search criteria

Advanced
Results 1-15 (15)
 

Clipboard (0)
None

Select a Filter Below

Year of Publication
Document Types
author:("fukui, tomoto")
1.  Expression of PAM50 Genes in Lung Cancer: Evidence that Interactions between Hormone Receptors and HER2/HER3 Contribute to Poor Outcome12 
Neoplasia (New York, N.Y.)  2015;17(11):817-825.
Non–small cell lung cancers (NSCLCs) frequently express estrogen receptor (ER) β, and estrogen signaling is active in many lung tumors. We investigated the ability of genes contained in the prediction analysis of microarray 50 (PAM50) breast cancer risk predictor gene signature to provide prognostic information in NSCLC. Supervised principal component analysis of mRNA expression data was used to evaluate the ability of the PAM50 panel to provide prognostic information in a stage I NSCLC cohort, in an all-stage NSCLC cohort, and in The Cancer Genome Atlas data. Immunohistochemistry was used to determine status of ERβ and other proteins in lung tumor tissue. Associations with prognosis were observed in the stage I cohort. Cross-validation identified seven genes that, when analyzed together, consistently showed survival associations. In pathway analysis, the seven-gene panel described one network containing the ER and progesterone receptor, as well as human epidermal growth factor receptor (HER)2/HER3 and neuregulin-1. NSCLC cases also showed a significant association between ERβ and HER2 protein expression. Cases positive for HER2 expression were more likely to express HER3, and ERβ-positive cases were less likely to be both HER2 and HER3 negative. Prognostic ability of genes in the PAM50 panel was verified in an ERβ-positive cohort representing all NSCLC stages. In The Cancer Genome Atlas data sets, the PAM50 gene set was prognostic in both adenocarcinoma and squamous cell carcinoma, whereas the seven-gene panel was prognostic only in squamous cell carcinoma. Genes in the PAM50 panel, including those linking ER and HER2, identify lung cancer patients at risk for poor outcome, especially among ERβ-positive cases and squamous cell carcinoma.
doi:10.1016/j.neo.2015.11.002
PMCID: PMC4681883  PMID: 26678909
NSCLC, non–small cell lung cancer; ER, estrogen receptor; PGR, progesterone receptor; HR, hazard ratio; HER2, human epidermal growth factor receptor 2; HER3, human epidermal growth factor receptor 3; FFPE, formalin-fixed, paraffin embedded; PCA, principal component analysis; DFS, disease-free survival; PFS, progression-free survival; OS, overall survival; TCGA, The Cancer Genome Atlas; PAM50, prediction analysis of microarray 50 gene set; IHC, immunohistochemistry; IPA, Ingenuity Pathway Analysis
2.  Matrix Metalloproteinase-19 Promotes Metastatic Behavior In Vitro and Is Associated with Increased Mortality in Non–Small Cell Lung Cancer 
Rationale: Lung cancer is the leading cause of cancer death in both men and women in the United States and worldwide. Matrix metalloproteinases (MMPs) have been implicated in the development and progression of lung cancer, but their role in the molecular pathogenesis of lung cancer remains unclear. We have found that MMP19, a relatively novel member of the MMP family, is overexpressed in lung tumors when compared with control subjects.
Objectives: To test the hypothesis that MMP19 plays a significant role in the development and progression of non–small cell lung cancer (NSCLC).
Methods: We have analyzed lung cancer gene expression data, immunostained lung tumors for MMP19, and performed in vitro assays to test the effects of MMP19 in NSCLC cells.
Measurements and Main Results: We found that MMP19 gene and protein expression is increased in lung cancer tumors compared with adjacent and histologically normal lung tissues. In three independent datasets, increased MMP19 gene expression conferred a poorer prognosis in NSCLC. In vitro, we found that overexpression of MMP19 promotes epithelial–mesenchymal transition, migration, and invasiveness in multiple NSCLC cell lines. Overexpression of MMP19 with a mutation at the catalytic site did not impair epithelial–mesenchymal transition or expression of prometastasis genes. We also found that miR-30 isoforms, a microRNA family predicted to target MMP19, is markedly down-regulated in human lung cancer and regulates MMP19 expression.
Conclusions: Taken together, these findings suggest that MMP19 is associated with the development and progression of NSCLC and may be a potential biomarker of disease severity and outcome.
doi:10.1164/rccm.201310-1903OC
PMCID: PMC4299607  PMID: 25250855
MMP19; epithelial–mesenchymal transition; metastasis; non–small cell lung cancer; miR-30
3.  Inherited variation in the ATP-binding cassette transporter ABCB1 and survival after chemotherapy for stage III-IV lung cancer 
Background
The ATP-binding cassette transporter gene ABCB1 and the glutathione S-transferase gene GSTP1 code for a multidrug resistance (MDR) protein and for a detoxifying phase II metabolic enzyme, respectively, with substrate specificities that include chemotherapy drugs commonly used to treat lung cancer.
Methods
We genotyped 11 ABCB1 and 8 GSTP1 single nucleotide polymorphisms (SNPs) in 698 white lung cancer patients (all current or former cigarette smokers) and used log-rank test statistics and proportional hazards regression to evaluate associations between SNP genotype and survival.
Results
Using data from all 698 cases, one SNP in ABCB1 (rs2235013) was statistically significantly associated with overall survival (p=0.038, log-rank test). Chemotherapy and stage jointly (p=0.025) significantly modified the association between rs2235013 and survival, with statistically significant (p=0.013, log-rank test) association observed in the subgroup of stage III-IV lung cancer patients who received chemotherapy as part of their first course of treatment (N=160; 93.1% non-small cell). Patients who inherited the minor T allele at ABCB1 rs2235013 experienced better overall and recurrence-free survival [hazard ratio, per minor T allele, (95% confidence interval): 0.66 (0.49-0.90) and 0.55 (0.31-0.95), respectively; adjusted for year of diagnosis, sex, age at diagnosis, cigarette pack years, and stage]. In addition, in the advanced-stage chemotherapy-treated subgroup, four ABCB1 SNPs (rs6949448, rs2235046, rs1128503, and rs10276036) in mutual high linkage disequilibrium with rs2235013 and an independent ABCB1 SNP (rs1045642) showed statistically significant association (p<0.05) with survival.
Conclusions
Inherited variation in ABCB1 may affect survival specifically in advanced-stage lung cancer patients who receive chemotherapy.
doi:10.1097/JTO.0000000000000262
PMCID: PMC4134100  PMID: 25122423
4.  MicroRNA expression profiling predicts clinical outcome of carboplatin/paclitaxel-based therapy in metastatic melanoma treated on the ECOG-ACRIN trial E2603 
Clinical Epigenetics  2015;7(1):58.
Background
Carboplatin/paclitaxel (CP), with or without sorafenib, result in objective response rates of 18–20 % in unselected chemotherapy-naïve patients. Molecular predictors of survival and response to CP-based chemotherapy in metastatic melanoma (MM) are critical to improving the therapeutic index.
Intergroup trial E2603 randomized MM patients to CP with or without sorafenib. Expression data were collected from pre-treatment formalin-fixed paraffin-embedded (FFPE) tumor tissues from 115 of 823 patients enrolled on E2603. The selected patients were balanced across treatment arms, BRAF status, and clinical outcome. We generated data using Nanostring array (microRNA (miRNA) expression) and DNA-mediated annealing, selection, extension and ligation (DASL)/Illumina microarrays (HT12 v4) (mRNA expression) with protocols optimized for FFPE samples. Integrative computational analysis was performed using a novel Tree-guided Recursive Cluster Selection (T-ReCS) [1] algorithm to select the most informative features/genes, followed by TargetScan miRNA target prediction (Human v6.2) and mirConnX [2] for network inference.
Results
T-ReCS identified PLXNB1 as negatively associated with progression-free survival (PFS) and miR-659-3p as the primary miRNA associated positively with PFS. miR-659-3p was differentially expressed based on PFS but not based on treatment arm, BRAF or NRAS status. Dichotomized by median PFS (less vs greater than 4 months), miR-659-3p expression was significantly different. High miR-659-3p expression distinguished patients with responsive disease (complete or partial response) from patients with stable disease. miR-659-3p predicted gene targets include NFIX, which is a transcription factor known to interact with c-Jun and AP-1 in the context of developmental processes and disease.
Conclusions
This novel integrative analysis implicates miR-659-3p as a candidate predictive biomarker for MM patients treated with platinum-based chemotherapy and may serve to improve patient selection.
doi:10.1186/s13148-015-0092-2
PMCID: PMC4457092  PMID: 26052356
Melanoma; MicroRNAs; Chemotherapy; Response; Biomarkers; Predictive
5.  Pathologic and Gene Expression Features of Metastatic Melanomas to the Brain (MBM) 
Cancer  2013;119(15):2737-2746.
Background
The prognosis of MBM is variable with prolonged survival in a subset. It is unclear whether MBMs differ from extracranial metastases (EcM) and primary melanomas (PrM).
Methods
To study the biology of MBM we performed histopathologic analysis of tumor blocks from patients' craniotomy samples and whole genome expression profiling (WGEP) with confirmatory immunohistochemistry (IHC).
Results
Mononuclear infiltrate and low intratumoral hemorrhage were associated with prolonged overall survival (OS). Pathway analysis of WGEP data from 29 such craniotomy tumor blocks demonstrated that several immune-related BioCarta gene sets were associated with prolonged OS. WGEP analysis of MBM in comparison with same-patient EcM and PrM showed that MBM and EcM were similar—but both differ significantly from PrM. IHC analysis revealed that peritumoral CD3+ and CD8+ cells were associated with prolonged OS.
Conclusions
MBMs are more similar to EcM compared to PrM. Immune infiltrate is a favorable prognostic factor for MBM.
doi:10.1002/cncr.28029
PMCID: PMC3901051  PMID: 23695963
Melanoma; Brain Metastases; Craniotomy Immune Infiltrate; Gene Expression Profiling
6.  Genetic variation in ESR2 and estrogen receptor-beta expression in lung tumors 
Cancer epidemiology  2013;37(4):518-522.
Objective
To investigate the association between inherited variation in the estrogen receptor beta (ERβ) gene (ESR2) and ERβ lung tumor expression, a phenotype that possibly affects survival differently in men and women.
Methods
We genotyped 135 lung cancer patients for 22 ESR2 single nucleotide polymorphisms (SNPs) and measured nuclear and cytoplasmic ERβ expression by immunohistochemistry (IHC) in their primary lung tumor. Distributing Allred ERβ IHC scores according to ESR2 genotype classified under a dominant genetic model, we used rank sum tests to identify ESR2 SNPs significantly associated (p<0.05) with ERβ expression.
Results
35%, 35%, and 29% of lung tumors showed no/low (Allred <6), intermediate (Allred 6 to 7), and maximal (Allred 8) cytoplasmic ERβ expression, whereas 13%, 27%, and 60% showed no/low, intermediate, and maximal nuclear ERβ expression. For SNPs rs8021944, rs1256061 and rs10146204, ERβ expression was higher according to the rank sum test in lung tumors from patients with at least one minor allele. For each of these three SNPs, the odds of maximal (Allred 8) relative to no/low (Allred <6) ERβ expression was 3-fold higher in tumors from patients with at least one minor allele than in tumors from patients homozygous for the common allele.
Conclusion
Inherited variability in ESR2 may determine ERβ lung tumor expression.
doi:10.1016/j.canep.2013.03.020
PMCID: PMC3684046  PMID: 23619141
lung cancer; genetic polymorphism; estrogen receptor
7.  Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers 
Cancer discovery  2013;3(7):761-769.
Genomic findings underscore the heterogeneity of head and neck squamous cell carcinoma (HNSCC)(1, 2). Identification of mutations that predict therapeutic response would be a major advance. We determined the mutationally altered, targetable mitogenic pathways in a large HNSCC cohort. Analysis of whole-exome sequencing data from 151 tumors revealed the PI3K pathway to be the most frequently mutated oncogenic pathway (30.5%). PI3K pathway-mutated HNSCC tumors harbored a significantly higher rate of mutations in known cancer genes. In a subset of HPV-positive tumors, PIK3CA or PIK3R1 was the only mutated cancer gene. Strikingly, all tumors with concurrent mutation of multiple PI3K pathway genes were advanced (stage IV), implicating concerted PI3K pathway aberrations in HNSCC progression. Patient-derived tumorgrafts with canonical and non-canonical PIK3CA mutations were sensitive to an m-TOR/PI3K inhibitor (BEZ-235) in contrast to PIK3CA wildtype tumorgrafts. These results suggest that PI3K pathway mutations may serve as predictive biomarkers for treatment selection.
doi:10.1158/2159-8290.CD-13-0103
PMCID: PMC3710532  PMID: 23619167
PI3K; mutation; BEZ-235; head and neck cancer
8.  CYP2A6 Genotype and Smoking Behavior in Current Smokers Screened for Lung Cancer 
Substance use & misuse  2013;48(7):490-494.
Functional CYP2A6 genetic variation partially determines nicotine metabolism. In 2005, we examined functional CYP2A6 variants associated with reduced metabolism (CYP2A6*2, CYP2A6*9, CYP2A6*4), smoking history, and change in smoking in 878 adult smokers undergoing lung cancer screening in an urban setting. At one year, 216 quit smoking for more than 30 days while 662 continued smoking. Compared to subjects who smoked 30 cigarettes per day at baseline, the odds of a reduced metabolism genotype was 52% higher in subjects smoking 20–29 cigarettes per day and 86% higher in subjects smoking less than 20 cigarettes per day (p-trend = 0.016). Reduced metabolism genotypes appeared unrelated to quitting. Though related to smoking dose, CYP2A6 may not influence cessation.
doi:10.3109/10826084.2013.778280
PMCID: PMC3788637  PMID: 23528144
smoking cessation; smoking initiation; cigarette smoking; genetics; cytochrome P450; nicotine metabolism
9.  Genetic variability in DNA repair and cell cycle control pathway genes and risk of smoking-related lung cancer 
Molecular carcinogenesis  2011;51(Suppl 1):E11-E20.
DNA repair and cell cycle control play an important role in the repair of DNA damage caused by cigarette smoking. Given this role, functionally relevant single nucleotide polymorphisms (SNPs) in genes in these pathways may well affect the risk of smoking-related lung cancer. We examined the relationship between 240 SNPs in DNA repair and cell cycle control pathway genes and lung cancer risk in a case-control study of white current and ex-cigarette smokers (722 cases and 929 controls). Additive, dominant and recessive genetic models were evaluated for each SNP. A genetic risk summary score was also constructed. Odds ratios (OR) for lung cancer risk and 95% confidence intervals (95% CI) were estimated using logistic regression models. Thirty-eight SNPs were associated with lung cancer risk in our study population at P<0.05. The strongest associations were observed for rs2074508 in GTF2H4 (Padditive=0.003), rs10500298 in LIG1 (Precessive=2.7×10−4), rs747658 and rs3219073 in PARP1 (rs747658: Padditive=5.8×10−5; rs3219073: Padditive=4.6×10−5), and rs1799782 and rs3213255 in XRCC1 (rs1799782: Pdominant=0.006; rs3213255: Precessive=0.004). Compared to individuals with first quartile (lowest) risk summary scores, individuals with third and fourth quartile summary score results were at increased risk for lung cancer (OR: 2.21, 95% CI: 1.66–2.95 and OR: 3.44, 95% CI: 2.58–4.59, respectively; Ptrend<0.0001). Our data suggests that variation in DNA repair and cell cycle control pathway genes is associated with smoking-related lung cancer risk. Additionally, combining genotype information for SNPs in these pathways may assist in classifying current and ex-cigarette smokers according to lung cancer risk.
doi:10.1002/mc.20858
PMCID: PMC3289753  PMID: 21976407
SNP; case-control; lung cancer
10.  Effects of ERCC2 Lys751Gln (A35931C) and CCND1 (G870A) polymorphism on outcome of advanced-stage squamous cell carcinoma of the head and neck are treatment dependent 
Background
Germline variation in DNA damage response may explain variable treatment outcomes from squamous cell carcinoma of the head and neck (SCCHN). Grouping patients according to stage and radiation treatment, we compared SCCHN survival according to ERCC2 A35931C (Lys751Gln, rs13181) and CCND1 G870A (Pro241Pro, rs9344) genotypes.
Methods
Recruiting a hospital-based SCCHN case series (all white, 24.7% female, mean age 58.4 years), this treatment outcome cohort study genotyped n=275 stage III-IV cases initially treated with radiation (with or without chemotherapy) and n=80 stage III-IV and n=130 stage I-II cases initially treated without radiation or chemotherapy and used Kaplan-Meier and Cox regression analysis to compare genotype groups according to overall, disease-specific, progression-free, and recurrence-free survival.
Results
ERCC2-35931 AA predicted worse survival in stage III-IV treated with radiation (multiply adjusted hazard ratio (HR) 1.66, 95% confidence interval (CI) 1.15-2.40; HR over the first three follow-up years 1.92, 95% CI 1.28-2.88) and better survival in stage III-IV not treated with radiation (HR 0.26, 95% CI 0.11-0.62). Unassociated with survival in stage III-IV treated with radiation (HR 1.00, 95% CI 0.67-1.51), CCND1-870 GG predicted better survival in stage III-IV not treated with radiation (HR 0.14, 95% CI 0.04-0.50). Survival in stage I-II did not depend on ERCC2 A35931C or CCND1 G870A genotype.
Conclusions
Promoting tumor progression in untreated patients, germline differences in DNA repair or cell cycle control may improve treatment outcome in patients treated with DNA damaging agents.
Impact
ERCC2 A35931C may help distinguish advanced stage SCCHN with better outcomes from radiation treatment.
doi:10.1158/1055-9965.EPI-11-0520
PMCID: PMC3210907  PMID: 21890746
11.  Genome-Wide Association Study of Survival in Non–Small Cell Lung Cancer Patients Receiving Platinum-Based Chemotherapy 
Background
Interindividual variation in genetic background may influence the response to chemotherapy and overall survival for patients with advanced-stage non–small cell lung cancer (NSCLC).
Methods
To identify genetic variants associated with poor overall survival in these patients, we conducted a genome-wide scan of 307 260 single-nucleotide polymorphisms (SNPs) in 327 advanced-stage NSCLC patients who received platinum-based chemotherapy with or without radiation at the University of Texas MD Anderson Cancer Center (the discovery population). A fast-track replication was performed for 315 patients from the Mayo Clinic followed by a second validation at the University of Pittsburgh in 420 patients enrolled in the Spanish Lung Cancer Group PLATAX clinical trial. A pooled analysis combining the Mayo Clinic and PLATAX populations or all three populations was also used to validate the results. We assessed the association of each SNP with overall survival by multivariable Cox proportional hazard regression analysis. All statistical tests were two-sided.
Results
SNP rs1878022 in the chemokine-like receptor 1 (CMKLR1) was statistically significantly associated with poor overall survival in the MD Anderson discovery population (hazard ratio [HR] of death = 1.59, 95% confidence interval [CI] = 1.32 to 1.92, P = 1.42 × 10−6), in the PLATAX clinical trial (HR of death = 1.23, 95% CI = 1.00 to 1.51, P = .05), in the pooled Mayo Clinic and PLATAX validation (HR of death = 1.22, 95% CI = 1.06 to 1.40, P = .005), and in pooled analysis of all three populations (HR of death = 1.33, 95% CI = 1.19 to 1.48, P = 5.13 × 10−7). Carrying a variant genotype of rs10937823 was associated with decreased overall survival (HR of death = 1.82, 95% CI = 1.42 to 2.33, P = 1.73 × 10−6) in the pooled MD Anderson and Mayo Clinic populations but not in the PLATAX trial patient population (HR of death = 0.96, 95% CI = 0.69 to 1.35).
Conclusion
These results have the potential to contribute to the future development of personalized chemotherapy treatments for individual NSCLC patients.
doi:10.1093/jnci/djr075
PMCID: PMC3096796  PMID: 21483023
12.  A sex-specific association between a 15q25 variant and upper aerodigestive tract cancers 
Background
Sequence variants located at 15q25 have been associated with lung cancer and propensity to smoke. We recently reported an association between rs16969968 and risk of upper aerodigestive tract (UADT) cancers (oral cavity, oropharynx, hypopharynx, larynx and esophagus) in women (odds ratio (OR) =1.24, P=0.003) with little effect in men (OR=1.04, P=0.35).
Methods
In a coordinated genotyping study within the International Head and Neck Cancer Epidemiology (INHANCE) consortium, we have sought to replicate these findings in an additional 4,604 cases and 6,239 controls from 10 independent UADT cancer case-control studies.
Results
rs16969968 was again associated with UADT cancers in women (OR=1.21, 95% confidence interval(CI)=1.08–1.36, P=0.001) and a similar lack of observed effect in men (OR=1.02, 95%CI=0.95–1.09, P=0.66) (P-heterogeneity=0.01). In a pooled analysis of the original and current studies, totaling 8,572 UADT cancer cases and 11,558 controls, the association was observed among females (OR=1.22, 95%CI=1.12–1.34, P=7×10−6) but not males (OR=1.02, 95%CI=0.97–1.08, P=0.35) (P-heterogeneity=6×10−4). There was little evidence for a sex difference in the association between this variant and cigarettes smoked per day, with male and female rs16969968 variant carriers smoking approximately the same amount more in the 11,991 ever smokers in the pooled analysis of the 14 studies (P-heterogeneity=0.86).
Conclusions
This study has confirmed a sex difference in the association between the 15q25 variant rs16969968 and UADT cancers.
Impact
Further research is warranted to elucidate the mechanisms underlying these observations.
doi:10.1158/1055-9965.EPI-10-1008
PMCID: PMC3070066  PMID: 21335511
genetic variants; 15q25; nicotinic acetylcholine receptor; upper aerodigestive tract cancers; cigarettes per day
13.  Correction: A Genome-Wide Association Study of Upper Aerodigestive Tract Cancers Conducted within the INHANCE Consortium 
McKay, James D. | Truong, Therese | Gaborieau, Valerie | Chabrier, Amelie | Chuang, Shu-Chun | Byrnes, Graham | Zaridze, David | Shangina, Oxana | Szeszenia-Dabrowska, Neonila | Lissowska, Jolanta | Rudnai, Peter | Fabianova, Eleonora | Bucur, Alexandru | Bencko, Vladimir | Holcatova, Ivana | Janout, Vladimir | Foretova, Lenka | Lagiou, Pagona | Trichopoulos, Dimitrios | Benhamou, Simone | Bouchardy, Christine | Ahrens, Wolfgang | Merletti, Franco | Richiardi, Lorenzo | Talamini, Renato | Barzan, Luigi | Kjaerheim, Kristina | Macfarlane, Gary J. | Macfarlane, Tatiana V. | Simonato, Lorenzo | Canova, Cristina | Agudo, Antonio | Castellsagué, Xavier | Lowry, Ray | Conway, David I. | McKinney, Patricia A. | Healy, Claire M. | Toner, Mary E. | Znaor, Ariana | Curado, Maria Paula | Koifman, Sergio | Menezes, Ana | Wünsch-Filho, Victor | Neto, José Eluf | Garrote, Leticia Fernández | Boccia, Stefania | Cadoni, Gabriella | Arzani, Dario | Olshan, Andrew F. | Weissler, Mark C. | Funkhouser, William K. | Luo, Jingchun | Lubiński, Jan | Trubicka, Joanna | Lener, Marcin | Oszutowska, Dorota | Schwartz, Stephen M. | Chen, Chu | Fish, Sherianne | Doody, David R. | Muscat, Joshua E. | Lazarus, Philip | Gallagher, Carla J. | Chang, Shen-Chih | Zhang, Zuo-Feng | Wei, Qingyi | Sturgis, Erich M. | Wang, Li-E | Franceschi, Silvia | Herrero, Rolando | Kelsey, Karl T. | McClean, Michael D. | Marsit, Carmen J. | Nelson, Heather H. | Romkes, Marjorie | Buch, Shama | Nukui, Tomoko | Zhong, Shilong | Lacko, Martin | Manni, Johannes J. | Peters, Wilbert H. M. | Hung, Rayjean J. | McLaughlin, John | Vatten, Lars | Njølstad, Inger | Goodman, Gary E. | Field, John K. | Liloglou, Triantafillos | Vineis, Paolo | Clavel-Chapelon, Francoise | Palli, Domenico | Tumino, Rosario | Krogh, Vittorio | Panico, Salvatore | González, Carlos A. | Quirós, J. Ramón | Martínez, Carmen | Navarro, Carmen | Ardanaz, Eva | Larrañaga, Nerea | Khaw, Kay-Tee | Key, Timothy | Bueno-de-Mesquita, H. Bas | Peeters, Petra H. M. | Trichopoulou, Antonia | Linseisen, Jakob | Boeing, Heiner | Hallmans, Göran | Overvad, Kim | Tjønneland, Anne | Kumle, Merethe | Riboli, Elio | Välk, Kristjan | Voodern, Tõnu | Metspalu, Andres | Zelenika, Diana | Boland, Anne | Delepine, Marc | Foglio, Mario | Lechner, Doris | Blanché, Hélène | Gut, Ivo G. | Galan, Pilar | Heath, Simon | Hashibe, Mia | Hayes, Richard B. | Boffetta, Paolo | Lathrop, Mark | Brennan, Paul
PLoS Genetics  2011;7(4):10.1371/annotation/9952526f-2f1f-47f3-af0f-1a7cf6f0abc1.
doi:10.1371/annotation/9952526f-2f1f-47f3-af0f-1a7cf6f0abc1
PMCID: PMC3084181
14.  A Genome-Wide Association Study of Upper Aerodigestive Tract Cancers Conducted within the INHANCE Consortium 
McKay, James D. | Truong, Therese | Gaborieau, Valerie | Chabrier, Amelie | Chuang, Shu-Chun | Byrnes, Graham | Zaridze, David | Shangina, Oxana | Szeszenia-Dabrowska, Neonila | Lissowska, Jolanta | Rudnai, Peter | Fabianova, Eleonora | Bucur, Alexandru | Bencko, Vladimir | Holcatova, Ivana | Janout, Vladimir | Foretova, Lenka | Lagiou, Pagona | Trichopoulos, Dimitrios | Benhamou, Simone | Bouchardy, Christine | Ahrens, Wolfgang | Merletti, Franco | Richiardi, Lorenzo | Talamini, Renato | Barzan, Luigi | Kjaerheim, Kristina | Macfarlane, Gary J. | Macfarlane, Tatiana V. | Simonato, Lorenzo | Canova, Cristina | Agudo, Antonio | Castellsagué, Xavier | Lowry, Ray | Conway, David I. | McKinney, Patricia A. | Healy, Claire M. | Toner, Mary E. | Znaor, Ariana | Curado, Maria Paula | Koifman, Sergio | Menezes, Ana | Wünsch-Filho, Victor | Neto, José Eluf | Garrote, Leticia Fernández | Boccia, Stefania | Cadoni, Gabriella | Arzani, Dario | Olshan, Andrew F. | Weissler, Mark C. | Funkhouser, William K. | Luo, Jingchun | Lubiński, Jan | Trubicka, Joanna | Lener, Marcin | Oszutowska, Dorota | Schwartz, Stephen M. | Chen, Chu | Fish, Sherianne | Doody, David R. | Muscat, Joshua E. | Lazarus, Philip | Gallagher, Carla J. | Chang, Shen-Chih | Zhang, Zuo-Feng | Wei, Qingyi | Sturgis, Erich M. | Wang, Li-E | Franceschi, Silvia | Herrero, Rolando | Kelsey, Karl T. | McClean, Michael D. | Marsit, Carmen J. | Nelson, Heather H. | Romkes, Marjorie | Buch, Shama | Nukui, Tomoko | Zhong, Shilong | Lacko, Martin | Manni, Johannes J. | Peters, Wilbert H. M. | Hung, Rayjean J. | McLaughlin, John | Vatten, Lars | Njølstad, Inger | Goodman, Gary E. | Field, John K. | Liloglou, Triantafillos | Vineis, Paolo | Clavel-Chapelon, Francoise | Palli, Domenico | Tumino, Rosario | Krogh, Vittorio | Panico, Salvatore | González, Carlos A. | Quirós, J. Ramón | Martínez, Carmen | Navarro, Carmen | Ardanaz, Eva | Larrañaga, Nerea | Khaw, Kay-Tee | Key, Timothy | Bueno-de-Mesquita, H. Bas | Peeters, Petra H. M. | Trichopoulou, Antonia | Linseisen, Jakob | Boeing, Heiner | Hallmans, Göran | Overvad, Kim | Tjønneland, Anne | Kumle, Merethe | Riboli, Elio | Välk, Kristjan | Voodern, Tõnu | Metspalu, Andres | Zelenika, Diana | Boland, Anne | Delepine, Marc | Foglio, Mario | Lechner, Doris | Blanché, Hélène | Gut, Ivo G. | Galan, Pilar | Heath, Simon | Hashibe, Mia | Hayes, Richard B. | Boffetta, Paolo | Lathrop, Mark | Brennan, Paul
PLoS Genetics  2011;7(3):e1001333.
Genome-wide association studies (GWAS) have been successful in identifying common genetic variation involved in susceptibility to etiologically complex disease. We conducted a GWAS to identify common genetic variation involved in susceptibility to upper aero-digestive tract (UADT) cancers. Genome-wide genotyping was carried out using the Illumina HumanHap300 beadchips in 2,091 UADT cancer cases and 3,513 controls from two large European multi-centre UADT cancer studies, as well as 4,821 generic controls. The 19 top-ranked variants were investigated further in an additional 6,514 UADT cancer cases and 7,892 controls of European descent from an additional 13 UADT cancer studies participating in the INHANCE consortium. Five common variants presented evidence for significant association in the combined analysis (p≤5×10−7). Two novel variants were identified, a 4q21 variant (rs1494961, p = 1×10−8) located near DNA repair related genes HEL308 and FAM175A (or Abraxas) and a 12q24 variant (rs4767364, p = 2×10−8) located in an extended linkage disequilibrium region that contains multiple genes including the aldehyde dehydrogenase 2 (ALDH2) gene. Three remaining variants are located in the ADH gene cluster and were identified previously in a candidate gene study involving some of these samples. The association between these three variants and UADT cancers was independently replicated in 5,092 UADT cancer cases and 6,794 controls non-overlapping samples presented here (rs1573496-ADH7, p = 5×10−8; rs1229984-ADH1B, p = 7×10−9; and rs698-ADH1C, p = 0.02). These results implicate two variants at 4q21 and 12q24 and further highlight three ADH variants in UADT cancer susceptibility.
Author Summary
We have used a two-phased study approach to identify common genetic variation involved in susceptibility to upper aero-digestive tract cancer. Using Illumina HumanHap300 beadchips, 2,091 UADT cancer cases and 3,513 controls from two large European multi-centre UADT cancer studies, as well as 4,821 generic controls, were genotyped for a panel 317,000 genetic variants that represent the majority of common genetic in the human genome. The 19 top-ranked variants were then studied in an additional series of 6,514 UADT cancer cases and 7,892 controls of European descent from an additional 13 UADT cancer studies. Five variants were significantly associated with UADT cancer risk after the completion of both stages, including three residing within the alcohol dehydrogenase genes (ADH1B, ADH1C, ADH7) that have been previously described. Two additional variants were found, one near the ALDH2 gene and a second variant located in HEL308, a DNA repair gene. These results implicate two variants 4q21 and 12q24 and further highlight three ADH variants UADT cancer susceptibility.
doi:10.1371/journal.pgen.1001333
PMCID: PMC3060072  PMID: 21437268
15.  The impact of genetic variation in DRD2 and SLC6A3 on smoking cessation in cohort of participants one year after enrollment in a lung cancer screening study 
Smoking cessation strategies continue to have disappointing results. By determining the interindividual genetic differences that influence smoking behaviors, we may be able to develop tailored strategies that increase the likelihood of successful cessation. This study attempts to determine genetic influences on the relationship between the dopamine pathway and smoking cessation by examining associations with a variable number tandem repeat variation in SLC6A3 and the DRD2 variants TaqIA (A2 vs. A1), TaqIB (B2 vs. B1), C957T (C vs. T), and -141C Ins/Del (C vs. Del). Baseline smokers in the Pittsburgh Lung Screening Study who provided information on smoking status one year later were evaluated. We frequency-matched those who were not abstinent at one year to those who were abstinent at one year by gender, decade of age, and time of enrollment (three month intervals) in a three to one ratio (N=881). Logistic regression was used to identify the effect of genotype on abstinence at one year. In a model containing the matching variables and other genotypes, DRD2 TaqIA was significantly associated with being abstinent at one year (p=0.01). Compared to participants who were homozygous TaqIA major allele (A2A2), participants who carried at least one minor allele (A1) were less likely to quit (Odds Ratio: 0.47, 95% CI: 0.24–0.94). The other dopamine receptor genotypes and the SLC6A3 genotype were not associated with smoking status at one-year. The association between DRD2 TaqIA and smoking cessation supports the hypothesis that genetic variation in the dopamine pathway influences smoking cessation.
doi:10.1002/ajmg.b.30801
PMCID: PMC2730224  PMID: 18563706
tobacco use cessation; genotype; case-control study; dopamine

Results 1-15 (15)